GLP1R and obesity disorder: There are several well-established actions of GLP-1, including stimulation of postprandial insulin secretion from β cells supporting development of GLP-1 medicines for type 2 diabetes (T2D), and reduction of appetite, enabling weight loss and approval of GLP-1-based medicines for the treatment of people with obesity [1].